Remissions after primary therapy in ovarian cancer is usually shortlived. Although intially responsive to a platinum and taxane-based therapy, recurrent disease is difficult to treat. Furthermore, there are few approved agents to treat recurrent ovarian cancer. Although patients that recur after 6 to 12 months of initial treatment may be retreated with a platinum plus taxane, those who relapse earlier or develop significant toxicity, may be given pegalated lipsomal doxorubicin, gemcitabine (in combination with platinum), etoposide, alkeran, topotecan, and/ or hexamethylmelamide . Unfortunately the response rate to these agents is generally less than 30%, and demonstrable survival benefits have not been shown. With the introduction of targeted drugs, such as trastuzumab in breast cancer, strategies in drug development have focused on the development of biologic agents that demonstrate selectivity for tumor tissue.Scholarly journal is a peer-reviewed journal in which scholarship relating to a particular academic discipline is published. Scholarly journals serve as forums for the introduction and presentation for scrutiny of new research, and the critique of existing research. Content typically takes the form of articles presenting original research, review articles, and book reviews. The term Scholarly journal applies to scholarly publications in all fields; this article discusses the aspects common to all academic field journals.
Last date updated on June, 2014